Summary
EudraCT Number: 2007-003262-17
Sponsor's Protocol Code Number: AG-1-2007. 
National Competent Authority: Germany - BfArM 
Clinical Trial Type: EEA CTA
Trial Status: Prematurely Ended
Date on which this record was first entered in the EudraCT database: 2008-07-08
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003262-17/DE/

A. Protocol Information
A.1 Member State Concerned: Germany - BfArM
A.2 EudraCT number: 2007-003262-17
A.3 Full title of the trial: Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation
A.3.2 Name or abbreviated title of the trial where available: CREATIVE-AF
A.4.1 Sponsor's protocol code number: AG-1-2007. 
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: University Hospital Magdeburg
B.1.3.4	Country: Germany
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: aprovel
D.2.1.1.2 Name of the Marketing Authorisation holder: sanofi-aventis
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: aprovel
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Irbesartan
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 150 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Capsule, hard
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules compared to placebo in patients with persistent/permanent atrial fibrillation. 
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules by more than 25% compared to placebo in patients with persistent/permanent atrial fibrillation. 

Target:
Examination of the study hypothesis in a prospective, randomized, placebo-controlled, double-blind crossover study in patients with persistent / permanent atrial fibrillation.

E.2.2 Secondary objectives of the trial: 
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: Patients with persistent/permanent  AF (> 2 months) 
CHADS2 Score > 2 
Age ³ 18 
Patient informed orally and in writing
Written informed consent of the patient

E.4 Principal exclusion criteria: §	Strong clinical evidence that prevents the temporary pause of therapy with AT II antagonists
§	Symptomatic bradycardia
§	Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac algorithm in use
§	Cardiac surgery or cardiac catheter ablation within the last 3 months
§	Typical angina pectoris symptoms at rest or during exercise
§	Known coronary artery disease with indication for intervention
§	Symptomatic peripheral vascular disease
§	Left ventricular ejection fraction < 35%
§	Myocardial infarction within 6 months of screening
§	Diastolic blood pressure > 110mm Hg at rest
§	Symptomatic arterial hypotension
§	Known renal artery stenosis
§	serum creatinin > 1.8 mval/l
§	chronic inflammatory disease
§	acute inflammatory disease (hsCRP > 20mg/L)
§	Relevant hepatic or pulmonary disorders
§	Hyperthyreosis manifested clinically and in laboratory
§	Known drug intolerance for AT II inhibitors
§	Females who are pregnant or breast feeding
§	Females of childbearing potential who are not using a scientifically accepted method of contraception
§	Participation in a clinical trial within the last 30 days
§	Drug addiction or chronic alcohol abuse
§	Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical study, Evidence of an uncooperative attitude

E.5 End points
E.5.1 Primary end point(s): Reduction of systemic levels of oxidative stress markers and adhesion molecules(hsCRP, ICAM, VCAM, MCP-1, vWF, TGFb1, TNF-a, Interleukin-6, 8isoProstaglandinF2a)
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: Yes
E.6.3 Therapy: Yes
E.6.4 Safety: No
E.6.5 Efficacy: No
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: Yes
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: Yes
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 5
E.8.5 The trial involves multiple Member States: Information not present in EudraCT
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 8
E.8.9.1 In the Member State concerned months: 12
E.8.9.1 In the Member State concerned days: 1

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: Information not present in EudraCT
F.4 Planned number of subjects to be included
F.4.1 In the member state: 60
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 60
F.4.2.2 In the whole clinical trial: 60

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2008-03-04
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2008-08-13

P. End of Trial
P. End of Trial Status: Prematurely Ended

